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Abstract
Background
The culmination of the drug development process is the compilation of a marketing
authorization application, the compiled technical information required to attain a license
to market a new drug product. Though large numbers of guidelines for drug development
are now available, significant questions continue to arise during the assessment of new
drug submissions by regulatory Agencies that slow the review/approval process. Such
questions also require deployment of increasingly strained resources within the
sponsoring company to address the issues raised. Such queries usually arise
unexpectedly and often require scientists to distract their attention from other research
<J
projects, confounding workflow management.
Methods
Based on a survey employing a questionnaire regarding the quality of pharmaceutical
new drug applications (NDAs), the present study has the primary objective of
quantitatively assessing FDA reviewers' perceptions of overall dossier quality,
appropriateness of the format/presentation of new drug applications and adherence to
available development guidelines by application sponsors. Secondarily, information
regarding frequency and significance of specific dossier questions raised during
regulatory review was compiled. The survey was directed at groups of reviewers within
1
the· disciplines of ChemistrylManufacturing, Nonclinical Biophannaceutical and
ClinicallMedical within the FDA.
Results
The respondents within each of the disciplines considered the overall quality of most of
the registration dossiers to be either "good" or "excellen(, though a significant
proportion were considered to be "fair" or "poor". The majority of reviewers within the
ChemistrylManufacturing, Nonclinical and Biopharmaceutical disciplines identified only
a few specific issues that usually cause delays in the review of new drug submissions.
However, most of the topics discussed within the ClinicallMedical section of New Drug
Applications were noted as leading to frequent questions of major significance to the
review of new products.
Conclusions
While some specific issues regarding the content of drug applications to the US FDA
may benefit from greater attention during drug development and the preparation of the'
application by drug sponsors, the overall quality of most submissions is considered to be
good by the FDA reviewers surveyed. Drug companies should consider this data, along
with information gathered during the review of previous submissions that they have
made, when allocating resources within their organizations to minimize the potential for
issues to be raised during the review of future applications.
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I. BACKGROUND
Over the past several years there has been increased competition within the
pharmaceutical industry for market share and revenues, both in countries with
predominantly open market policies for health care funding and those with more
socialized medical payment systems. In the US, the proliferation of managed care
providers, along with increased public scrutiny of pricing policies, has limited the extent
of pharmaceutical drug price increases. This situation has brought about increased efforts
to reduce operating costs across the pharmaceutical industry which have taken place
through several strategic approaches, including vertical integration, horizontal mergers
and downsizing. These increasingly competitive conditions have led to an emphasis by
corporate management to increase the speed and efficiency of their drug development
process, so that new products can be brought to market both to secure revenues and
strengthen market share, while reducing operating expenses in all aspects of
development, production and sales. As a result of these efforts, recent data has suggested
that new drug development time has been reduced. Successful drug development includes
generation·of the data necessary and sufficient to obtain prompt regulatory approval of
products, justify commercially satisfactory pricing and· support optimum market
positioning. This is ideally completed in a competitive time frame and at an efficient
cost. The culmination of the drug development process is the compilation of a marketing
authorization application, or MAA (MAA is a generic term for the compiled technical
information required to attain a license to market a new drug product. In the US the
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application is referred to as the NDA, or New Drug Application). The MAA is a large
and complex document that includes both raw and summarized· data gathered during the
development of a drug product. Scientific review and approval of this dossier by a
responsible regulatory body is necessary in order to obtain licensure to commercialize a
new drug product within a particular jurisdiction.
In the US, regulation of pharmaceutical products is one of the many responsibilities of
the Food and Drug Administration (FDA). The mission of FDA's Center for Drug
Evaluation and Research (CDER) is to ensure that safe and effective drugs are available
to the American people (The FDA's Center for Biologics Evaluation and Research,
CBER, is responsible for all products developed thrqugh the use of biotechnology). In
order to accomplish this mission, one of the key activities within the Agency is the
assessment of new drug products. This assessment is a multifunctional review, which
considers several key areas of product quality, safety and efficacy. Similarly, the
European Medicines Evaluation Agency (EMEA) is responsible for the management of
drug registration across the European Union. While national regulatory agencies remain
in each of the EU countries, their responsibilities for registration of new drug products
now represent part of a coordinated effort, along with the other EU member states,
towards approval throughout the region.
Together with the Japanese Ministry of Health, the FDA and EMEA have joined with
pharmaceutical industry organizations in the three regions to form the International
4
Conference on Harmonization (JCH). Since the initial meeting of this group in 1991, the
ICH has made significant strides towards the creation of, and agreement on, many
guidelines for drug development which have eliminated much of the variability which has
existed among the requirements for drug approval in these markets. One of the more
ambitious undertakings of the ICH has been the definition of a Common Technical
Document (CTD), which is meant to define the format and contents of new drug
applications that can be submitted in any of the markets within these regions. The ICH
guidance for the CTD has recently been issued, and the FDA is now accepting
submissions in this format.
Concurrent with the ICH initiatives, there have been significant steps taken in recent
years to reduce regulatory review times within the FDA and ex-US health authorities.
Drug application sponsors must now contribute "user fees" along with their drug
submissions·in order to help provide the resources necessary to conduct the governments'
regulatory function. In return, the FDA and the EMEA have agreed to commit to certain
review time goals. These efforts have resulted in reduced approval times over· the past
several years as reflected in Annual Reports from both the FDA and EMEA Annual
Reports). However, the time for regulatory assessment can be significantly impacted by
the preparation of responses to questions raised during application review, which may
effectively stop the review clock. Such response preparation can thus result in substantial
delays to product commercialization, along with the associated competitive disadvantages
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and/or decreased revenue potential. Minimizing the tim~ to market also maximizes the
effective patent life (marketexclusivity) of a product.
Though large numbers of specific guidelines for drug development are now available,
significant questions continue to arise during regulatory reviews of new drug submissions
to regulatory Agencies. Such questions not only slow the process as it is occurring within
a reviewing agency, they also require deployment of increasingly strained resources
within the sponsoring company to address the issues raised. Such queries usually arise
unexpectedly and often require scientists to distract their attention from other research
projects, confounding workflow management.
Literature Review
There is little available literature addressing the necessary activities to increase the
efficiency of the drug approval process, most focusing on improving the speed of
regulatory agency action, and more specifically the role of the government body towards
this objective. David Jefferys (1995) has written on the potential for increasing the
efficiency of the regulatory review process, focussing on the steps taken at the UK
Medicines Control Agency (MCA) where he was Head of the Licensing Division. The
bulk of this publication explains the initiatives of the MCA towards establishing a state of
the art regulatory agency, including manpower expansion, information technology
investments.and management efforts. In the article he mentions the occasional "poor
dossier" which slows the review of an application based on "good science". Though he
6
does not detail the qualities considered valuable in either of these terms, the suggestion is
made that there is room for improvement on the side of industry to help decrease review
times.
G. Tabusso (1995) has addressed quality education and its relevance in the development
of pharmaceutical products. Tabusso emphasizes the need to integrate disciplines
involved in drug development in order to gain a cohesive approach to research and
assessment of the product's performance. She writes that an educational attitude towards
the discovery of a product's properties, along with a conscious, flexible approach to
implementation of rules and standards of drug development, is needed to best assure total
quality management in the process, and the generation of a high quality marketing
application. While this article provides sound advice to pharmaceutical research
scientists, it discusses only generalities and does not relate any specific criticisms of the
format and content of regulatory submissions.
An attempt to provide practical advice on increasing registration application quality is
provided in an article by Jonathan Cook (1990), a research analyst at the FDA. His work
intended to identify ways in which drug application sponsors could improve registration
dossier reviewability, though he limited his focus to, application format/indexing, without
consideration of the scientific data contained in applications per se.· More recently, Jim
Morrison of the FDA has written in the Agency's monthly bulletin of reviewers' "pet
7
peeves", which touches on submission quality, as well as industry interactions with .the
Agency.
The issues noted in his article are again general in nature, however he notes that overall
dossier quality seems to be improving..
An article by Louis Lasanga (1995) focuses on the value of discussions between sponsors
and the FDA, both during development and prior to registration submissions, in order to
agree upon the appropriate format and content for individual applications. Such
discussions with the FDA have been possible for several years, though the amount that
industry has taken advantage of the opportunity in the past is questionable. Outside of
the US, such meetings have only recently become possible in some countries, but early
evidence supports the value of such meetings as well.
In summary, the literature available does not include a direct assessment of the opinions
of pharmaceutical regulators as to the quality of drug registration applications which they
review, and what specific areas of these documents require further improvement in order
to support shorter review times.
Rationale for Research
Missing from the ongoing discussions regarding how to increase the efficiency of drug
development has been a clear identification of the quality aspects of marketing
8
applications where improvement by registration application sponsors is most needed.
Though drug companies can gain insights into ways in which these·applications could be
improved through consideration' of their past experiences, general opinions from national
authorities on dossier quality may help companies to generate higher quality applications,
by identifying areas within these applications which could be improved and potentially
reducing thenumber of queries generated during regulatory reviews.
The research described in this report attempts to identify the most frequent andlor
significant areas of deficient marketing application quality, according to application
reviewers within the FDA. The information accumulated should be valuable to
companies preparing drug product marketing applications by indicating areas of these
submissions which may require greater focus, allowing resources to be more effectively
used during dossier compilation and leading to quicker approvals/product launches by
minimizing the potential for delays during agency review
Regulatory dossier overview
In addition to administrative documentation that is specific to each country/region, the
four functionally distinct technical areas of marketing applications which support the
quality, safety and efficacy of a new drug product, which are normally reviewed by ,
separate personnel within regulatory bodies, are:
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• Chemistry/manufacturing - issues regarding both the active drug
substance ,and the formulation of the drug product,_which includes
inactive ingredients
• Nonclinical - animal studies of the potentially therapeutic and,
toxicological effects of the product
• Biopharmaceutical - studies of the absorption, metabolism, and
excretion of the product, including issues such as drug interactions
• CIinicaUMedical - safety and efficacy studies of the product in the
intended patient population
The quality of the different sections of marketing applications specific to these functional
areas has been assessed separately through this research.
2. STUDY OBJECTIVES
Based'on a questionnaire developed to assess both specific and general issues regarding
the quality of pharmaceutical marketing applications submitted to the US FDA, the
following study objectives has been addressed.
10
Primary Objective
Quantify FDA reviewers' perceptions of overall dossier quality, appropriateness
of the format/presentation of. new drug applications and adherence to available
development guidelines by application sponsors.
These questions were meant to gauge the· satisfaction of FDA regulators with the
applications that they review. Besides an overall assessment of quality, the reviewers
were asked to assess the content (adherence to guidelines) and format
(organization/presentation) as components of application quality (see questionaire in
Appendix 1).
Secondary Objective
Based on a summary of reviewer responses regarding frequency and significance
of specific dossier contents, identify areas of greatest perceived deficiency and
assess the potential impact of such deficiencies on the time required to process
registration applications
This was achieved by requesting their input on particular issues which are considered
during drug application review, as organized in the format of the Common Technical
Document (see questionaire in Appendix 1).
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3. RESEARCH PLAN
In· order to measure and assess the perception of regulatory agency personnel regarding.
the quality of new drug marketing applications, a questionnaire was developed which
included two types of questions: 1) questions which request a quantitative distribution
estimate of various aspects of application quality, and 2) questions regarding the
frequency and significance of specific issues raised during regulatory reviews. The
primary survey was planned to address the US FDA. However, in order to facilitate
potential use of this tool to compare responses from countries outside the US with those
of the FDA, the outline of the ICH Corinnon Technical Documentwas used as a list of
topics covered in a drug application. This outline provides the best available listing of
issues addressed in marketing applications across regional boundaries. It will also
expected to emerge as the standard format for marketing applications across countries, so
that the tool could be used again in the future, perhaps to assess changes in perceptions of
dossierquality over time.
Initial dispatch of the questionnaire was limited to the US FDA's Center for Drug
Evaluation and Research (CDER). Twenty-five questionnaires ~ere distributed for each
of three functional areas (chemistry/manufacturing, nonclinical, and biopharmaceutical).
For the clinical/medical area 50 questionnaires were dispatched as this is the area covered
by the largest number of reviewers. A 60% response rate was anticipated, which was
estimated to provide a database sufficient to provide meaningful results.
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For the questions regarding distribution of applications among four levels of quality (see
pie chart below), responses were compiled and an average distribution determined.
Excellent _%
The following general quality criteria were addressed for each functional area using the
questionaire included in Appendix 1.
• Overall quality
• Adherence to relevant guidelines
• Organization/presentation
In addition, the clinical reviewers were asked to separately assess the adequacy of
marketing applications to demonstrate the efficacy and safety of new products.
For the questions regarding specific topics covered within the four functional areas of the
applications, responses are presented as a sum of the raw data. Those topics that were
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identified as being ofmajor significance (majority of respondents) and!or were frequently
topics of review queries within each functional area are identified in a separate listing.
4. STATISTICAL METHODS
Descriptive statistics were applied to the data collected regarding the general dossier
quality assessments.
5. RESULTS
Overall, the response rate to the questionnaire was approximately 75%, somewhat higher
than anticipated. Data below reflect information collected from the following number of
respondents.
Questionaires Number Completed Response Rate (%)
Distributed
Chemistry/ 25 16 64
Manufacturing
Nonclinical 25 21 84
Biophannaceutics 25 18 72
ClinicallMedical 50 37 ,74
Total 125 92 74
Results are reported separately below for each of the functional disciplines.
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5.1 CHEMISTRY/MANUFACTURING
5. 1. 1 Overall Application Quality
Figure l.a Assessment of ChemistrylManufacturing dossier - overall quality
Excellent 9.4%
Fair 26.9%
Figure l.b Assessment of ChemistrylManufacturing dossier - adherence to
guidelines
Excellent
6.1%
Fair 34.3%
15
Good 55.5%
Figure I.e Assessment of ChemistrylManufacturing dossier - organization/
presentation
Excellent 14%
Good 62%
A greater proportion of applications was considered to be of poor/fair quality with
regards to adherence to guidelines (38%) than organization/presentation (24%). 34% of
the applications were considered to have an overall quality rating of poor/fair.
5.1.2. Specific Technical Issues
The following is a compilation of the responses regarding frequency and significance of
specific issues raised during regulatory reviews of chemistry/manufacturing data. Those
items noted as being of both major significance and frequent incidence included:
. /
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Drug Substance (active ingredient)
Justification of Specification
Stability (shelf life)
Drug Product (complete fonnulation)
Control of Drug Product/Specification
Stability (shelf life)
Those issues considered as being of less than major significance but were frequently the
topic of Ag~ncy queries included:
Control of Drug Substance I Specification
Those issues considered to be of major significance but raised issues less than frequently
included:
Control of Critical Steps and Intennediates
Description of Manufacturing Process
and Process Controls
Control of Excipients I Specifications
17
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Table}. Tabulated Summaries of responses to questionnaire regarding frequency and significance
of ChemistryfManufacturing questions raised during regulatory review
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Drug Substance
I. General Information (Nomenclature, Structure,
General Properties) 16 0 0 16 0 0
2. Manufacture
2.1 Manufacturer(s) 16 0 0 16 0 0
2.2 Description of Manufacturing Process
and Process Controls 0 13 3 0 II 5
2.3 Control of Materials 0 12 4 0 13 3
2.4. Control of Critical Steps and Intermediates 0 14 2 0 8 8
2.5 Process Validation or Evaluation I 14 I I 14 I
2.6 Manufacturing Process Development 2 14 0 14 2 0
:0
3. Characterization
3.1 Elucidation of Structure 12 4 0 0 I 0
3.2 Impurities 3 13 0 0 3 0
4. Control of Drug Substance
4.1 Specification 0 4 12 0 10 6
4.2 Analytical Procedure 2 13 1 4 12 0
4.3 Validation of Analytical Procedures 0 14 2 5 11 0
4.4 Batch Analyses 4 11 1 14 2 0
4.5 Justification of Specification 0 6 10 0 2 12
5. Reference Standards or Materials 13 3 0 8 8 0
6. Container Closure System 12 4 0 15 I 0
7. Stability 0 7 9 0 I 15
Table 1. Tabulated Summaries of responses to questionnaire regarding frequency and significance
of ChemistrylManufacturing questions raised during regulatory review (conI.)
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Drug Product
J. Description and Composition 13 3 0 9 7 0
2. Pharmaceutical Development 14 2 0 15 I 0
3. Manufacture
3.1 Manufacturer(s) 15 I 0 16 0 0
3.2 Batch Formula 14 2 0 3 13 0
3.3 Description of Manufacturing Process
and Process Controls 0 15 I 0 6 JO
3.4 Controls of Critical Steps and Intermediates 4 7 5 0 12 4
3.5 Process Validation or Evaluation 11 4 I 8 8 0
4. Control of Excipienls
4.1 Specifications 0 13 3 0 5 11
N 4.2 Analytical Procedures 5 10 I I 13 2
0 4.3 Validation of Analytical Procedures 2 12 2 3 13 0
4.4 Justification of Specifications 4 11 I 0 12 4
4.5 Excipients of Human or Animal Origin 14 2 0 0 7 9
4.6 Novel Excipients 15 1 0 6 9 I
5. Control of Drug Product
5.1 Specification 0 4 12 0 7 9
5.2 Analytical Procedures 0 10 6 0 II 5
5.3 Validation of Analytical Procedures I 8 7 2 10 4
5.4 Batch Analyses 6 6 4 2 11 3
5.5 Justification for Specification 3 II 2 0 10 6
6. COnlainer Closure System 10 6 0 14 2 0
7. Stability 0 4 12 0 2 14
8. Other Information
8.1 Executed Batch Records 15 I 0 3 12 I
8.2 Method Validation Package JO 5 1 0 13 3
8.3 Comparability Protocols 15 I 0 16 0 0
5.2. NONCLINICAL
5.2.1. Overall Application Quality
Figure 2.a Assessment of Nonclinical dossier - overall quality
Excellent
12.8%
Good 55.0%
\...
Figure 2.b Assessment of Nonclinical dossier - adherence to guidelines
Excellent
4.6%
Fair 30.3%
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Figure 2.c Assessment of Nonclinical dossier - organization/presentation
Excellent
11.9%
Good 51.9%
Similar proportions of applications were considered to be of poor or fair quality with
regards to adherence to guidelines (34%) and organization/presentation (37%), as well as
overall quality (32%).
5.2.2. Specific Technical Issues
The following is a compilation of the responses regarding frequency and significance of
specific issues raised during regulatory reviews of nonclinical data.
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Those items noted as being of both major significance an4 frequent incidence included:
Carcinogenicity I Long-term studies
There were no issues considered to be of less than major significance but frequently the
topic of Agency queries.
Those issues considered being of major significance that the majority of respondents
considered to raise issues less often than frequently included:
Primary Pharmacodynamics
Pharmacodynamic Drug Interactions
Kinetics (including in vivo studies of absorption and excretion, including
excretion in milk,. of parent drug and/or metabolites(s))
Pharmacokinetic Drug Interactions (nonclinical)
Fertility and early embryonic development
Embryo-fetal development
Prenatal and postnatal development, including maternal
function
23

Table 2. Tabulated Summaries of responses to questionnaire regarding
frequency and significance of nonclinical questions raised during regulatory review (cont.)
Frequency
Rare Occasional Frequent.
Significance
Minor Moderate Major
7. Other Toxicity Studies
7.1 Antigenicity I3 8 0 0 15 6
7.2 Immunotoxicity 15 6 0 0 14 7
7.3 Mechanistic studies I3 8 0 7 13 1
7.4 Dependence 19 2 0 7 12 2
7.5. Metabolites 16 5 0 0 20 1
7.6 Impurities 15 6 0 6 14 1
N
Vl
<
5.3. BIOPHARMACEUTICS
5.3.1. Overall Quality Assessment
Figure 3.a Assessment of Biopharmaceutics dossier - overall quality
Excellent
1.5%
Fair 36.8% Good 55.0%
Figure 3.b Assessment of Biopharmaceutics dossier - adherence to guidelines
Excellent
4.4%
Fair 36.0%
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Good 55.0%
Figure 3.e Assessment of Biophannaceutics dossier - organization/presentation
Excellent
11.2%
Good 47.2%
Similar proportions of applications were considered to be of poor or fair quality with
regards to adherence to guidelines (41%) and organization/presentation (42%), as well as
overall quality (43%).
5.3.2. Specific Technical Issues
There were no items noted as being frequently the topic of Agency queries.
The only issue considered being of major significance, though it was considered to result
in issues being raised less than fre~y by Biophannaceutics reviewers was Hepatic
Metabolism and Interaction Studies.
27
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Table 3. Tabulated Summaries ofresponses to questionnaire regarding
frequency and significance of Biopharmaceutics questions raised during regulatory review
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Bioavailability and Bioequivalence
1. Bioavailability 0 10 8 0 15 3
2. Bioequivalence 0 7 11 0 14 4
3. In Vitro-In Vivo Comparisons 3 12 3 2 16 0
4. Bioanalytical and Analytical Methods for Human Studies 10 8 0 8 10 0
Studies Using Human Biomaterials Pertinent to Absorption or Disposition
1. Plasma Protein Binding 9 9 0 4 14 0
N 2. Hepatic Metabolism and Interaction Studies 2 14 2 0 6 12\D
3. Studies Using Other Human Biomaterials 14 4 0 10 8 0
Human Pharmacokinetics (PK)
1. Healthy Subject PK and Initial Tolerability Studies 7 11 0 14 4 0
2. Patient PK and Initial Tolerability Studies 6 12 0 12 6 0
3. Intrinsic Factor PK Studies 9 9 0 4 14 0
4. Extrinsic Factor PK Studies 9 9 0 4 10 4
S. Population PK Studies 1 9 8 2 10 6
Human Pharmacodynamics (PD)
1. Healthy Subject PK and PKJPD Studies 12 6 0 10 8 0
2. Patient PK and PKJPD Studies 5 13 0 9 9 0
~.4.CLINICAUMEDICAL
5.4.1. Overall Quality Assessment
Figure 4.a Assessment of Clinical dossier - overall quality
Excellent
5.4%
Fair 35.0%
Good 55.6%
Figure 4.b Assessment of Clinical dossier - adherence to guidelines
Excellent
10.7%
Good 54.6%
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Figure 4.c Assessment of Clinical dossier - organization/presentation
Excellent
2.2%
Fair 35.7% Good 55.4%
The proportions of applications that were considered to be of poor or fair quality differed
with regards to adherence to guidelines (35%) and organization/presentation (44%), as
well as overall quality (39%). The proportion of applications considered to adequately
(good or excellent) demonstrate the efficacy and safety of new drugs were similar (61 %
and 57%, respectively - see below).
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Figure 4. d·Assessment of Clinical dossier - demonstration of efficacy
Excellent
5.4%
Fair 35.0% Good 55.1%
Figure 4.e Assessment of Clinical dossier - demonstration of safety
Excellent
2.1%
Fair 36.4%-
32
Good 55.0%
5.4.2. Specific Technical Issues
Except for theUncontrolled Studies and Drug abuse/overdose topics within the clinical
section, all other areas of the clinical section were rated as being of major importance and
were frequently the topic of issues raised during regulatory reviews.
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Table 4. Tabulated Summaries of responses to questionnaire regarding
frequency and significance of clinical questions raised during regulatory review
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Efficacy and Safety Studies
\. Controlled Clinical Studies Pertinent to the Claimed Indication 0 2 35 0 0 37
2. Uncontrolled Clinical Studies 5 30 2 7 30 0
w ( 4. Analyses of Data From More Than One Study.;:. (integrated summaries>
31 Efficacy 0 0 37 0 0 37
3,2 Safety 0 0 37 0 0 37
Drug Abuse and Overdose Information 27 10 0 19 18 0
Integrated Summary of Benefits and Risks 0 7 30 0 0 37
, 6. DISCUSSION
The high response rate to this survey by FDA reviewers is encouraging to those
engaged in the drug development process, and I believe reflects the FDA's increased
willingness to work with the pharmaceutical industry to foster more effective
pharmaceutical research. The results suggest that overall the Agency views the
quality of New Drug Applications positively, but there remains room for
improvement.
To aid in the optimization of the drug development effort, particularly with regard to
the role of the regulatory affairs professional in orchestrating the compilation of high
quality registration applications for new drugs, the following issues are suggested as
specific areas which may benefit from greater focus during the preparation of
marketing authorization applications.
Those items noted as being of both "major" significance and "frequent" incidence by'
a majority of respondents, which should be considered as a priority to increase
.application quality, included:
ChemistrylManufacturing
Drug Substance (active ingredient)
Justification of Specification
Stability (shelf-life)
35
· Drug Product (complete formulation)
Control of Drug Product/Specification
Stability (shelf-life)
Nonclinical
Carcinogenicity / Long-term studies
Clinical/Medical
Except for the Uncontrolled Studies and Drug abuse/overdose topics within the
clinical section, all areas of the clinical section were rated as being of major
importance and were frequently the' topic of issues raised during regulatory reviews.
This included controlled clinical trials and the integrated safety, efficacy and
benefit/risk assessments. Application summaries of efficacy and safety data were
considered as similar in quality. A more detail specific questionaire may be useful to
.elucidate the concerns of medical reviewers at FDA.
Those issues considered being of less than major significance but were frequently the
topic of Agency queries included:
Chemistry/Manujacturing
Control of Drug Substance / Specification
Those issues considered being of major significance but raised issues less than
frequently included:
Chemistry/Manufacturing
36
Control ofCritical Steps and Intern.1ediates
Description of Manufacturing Process
and Process Controls
Control of Excipients I Specifications
Nonclinical
Primary Pharmacodynamics
Pharmacodynamic Drug Interactions
Kinetics (including in vivo studies of absorption and excretion, including
excretion in milk, of parent drug andlor metabolites(s))
Pharmacokinetic Drug Interactions (nonclinical)
Fertility and early embryonic development
Embryo-fetal development
Prenatal and postnatal development, including maternal
function
Biopharmaceutics
Hepatic Metabolism and Interaction Studies
Comparisons across functions
A tabulated presentation of the results of questions on the distribution of application
quality levels among the four disciplines surveyed follows.
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·Overall Quality
Excellent Good Fair Poor
Chemistry! 9.4 55.9 26.9 7.8
Manufacturing
Nonclinical 12.8 55.0 25.7 6.6
Biophannaceutics 1.5 55.0 36.8 6.7
ClinicallMedical 5.4 55.6 35.0 4.1
Adherence to Guidelines
Excellent Good Fair Poor
Chemistry! 6.1 55.5 34.3 4.1
Manufacturing
Nonclinical 4.6 61.2 30.3 3.9
Biophannaceutics 4.4 55.0 36.0 4.6
ClinicallMedical 10.7 54.6 28.1 6.5
38
OrganizationlPresentation
Excellent Good Fair Poor
Chemistry! 11.9 56;6 24.7 6.9
Manufacturing
Nonclinical 11.9 51.9 29.7 6.5
Biophannaceutics 11.2 47.2 35.1 6.5
ClinicallMedical 2.2 55.4 35.7 6.6
.
Amongst the various disciplines, distribution of responses regarding the general level
of quality of New Drug Applications was remarkably similar in general. While the
majority of applications were considered to be "good" or "excellent", a significant
proportion was considered to be only "fair'.' or "poor". This suggests that there is
room for improvement in many of the applications received by the FDA which may
benefit from additional emphasis and time spent on application preparation. and
discussion of the contents with the Agency prior to submission.
Implications for future study
While these data are very interesting, they reflect only the opinions of the US FDA.
Further study regarding the opinions of regulators in Europe and Japan would also be
important as drug development becomes an increasingly global endeavor. It would
also be interesting to see if the perceived quality of drug applications changes over
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time by redressing the Agency with this questionaire at a future time, perhaps in 3 to
5 years.
The information gathered from this research should be of significant interest and
value to members of the pharmaceutical industry. The resulting analyses have
potential implications for ways in which drug sponsors prepare registration
applications, by presenting the perceptions of regulatory bodies as to the overall
quality and identifying particular areas within such applications in which questions
are frequently raised by the FDA, hopefully improving the efficiency of both drug
developers and Agencies. Improvement in addressing all of the above issues could
both decrease review times and reduce the number of questions raised during
regulatory reviews. However, the relevance of the data obtained from thIS survey will
need to be considered with regard to the costs as well as any timing concerns during
drug development. Assessment of these concerns will no doubt vary by company.
40
7. BIBLIOGRAPHY
Cook, J.; "Plain and Simple Advice for Improving NDAs." Pharmaceutical
Executive, Vol. 10(12), pp. 64-68, 1990.
EMEA Annual Report, 1999.
FDA Annual Report, 1999.
Jefferys, D., "Can the drug regulatory process be made more efficient? -A view from
the Medicines Control Agency." Drug Information Journal, Vol. 29, pp. 1071-1076,
1995.
Lasagna, L.; "Improving the Drug Development Process: Needed Reforms." Drug
Information Journal, Vol. 29, pp. 415-424,1995.
Morrison, J.; "CDER's Pet Peeves - Part 1." News Along the Pike, p.3, December 30,
1999.
41
8. APPENDICES
Appendix 1. Copy of Questionnaire
Appendix 2. Cirriculum Vitae for Fred Henry
42
Appendix 1. Copy of Questionnaire .
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ASSESSMENT OF DRUG REGISTRATION APPLICATION
DEFICIENCIES
. QUESTIONAIRE FOR REGULATORY AUTHORITY
PERSONNEL
Prepared by Fred Henry
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JCHEMISTRY/MANUFACTURING QUESTIONNAIRE
1) Please estimate the percentage of chem'istry/manufacturing sections of
marketing license applications that are of the following overall quality
levels: '
Excellent _%
2) How would you rate the applications reviewed within your agency,
according to the following criteria:
',: Adherence to relevant guidelines
"h
Excellent _%
45
Organization/presentation
Excellent
Please rate the following topics of product license app.lications as to the
frequency of questions raised during the regulatory review process, and
the significance of these questions to the product's approval.
46
CHEMISTRY, MANUFACTURING AND CONTROLS
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Drug Substance
1. General Infonnation (Nomenclature, Structure,
General Properties) 0 0 o. 0 0 0
2. Manufacture
2.1 Manufacturer(s) 0 0 0 0 0 0
.j:>
--J
2.2 Description of Manufacturing Process
and Process Controls 0 0 0 0 0 0
2.3 Control of Materials 0 0 0 0 0 0
2A.Control of Critical Steps and Intennediates 0 0 0 0 0 0
2.5 Process Validation or Evaluation 0 0 0 0 0 0
2.6 Manufacturing Process Development 0 0 0 0 0 0
3. Characterization
3.1 Elucidation of Structure 0 0 0 0 0 0
3.2 Impurities 0 0 0 0 0 0
Frequency i::llgnlllCanCI;
Rare Occasional Frequent Minor Moderate Major
4. Control of Drug Substance
4.1 Specification 0 0 0 0 0 0
4.2 Analytical Procedure 0 0 0 0 0 0
4.3 Validation of Analytical Procedures 0 0 0 0 0 0
4.4 Batch Analyses 0 0 0 0 0 0
4.51ustification of Specification 0 0 0 0 0 0
.. 5. Reference Standards or Materials 0 0 0 0 0 000
6. Container Closure System 0 0 0 0 0 0
7. Stability 0 0 0 0 0 0
Drug Product
1. Description and Composition 0 0 0 0 0 0
2. Pharmaceutical Development 0 0 0 0 0 0
3. Manufacture
3.1 Manufacturer(s) 0 0 0 0 0 0
3.2 Batch Formula 0 0 0 0 0 0
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
3.3 Description of Manufacturing Process
and Process Controls 0 0 0 0 0 0
3.4 Controls of Critical Steps and Intennediates 0 0 0 0 0 0
3.5 Process Validation or Evaluation 0 0 0 0 0 0
4. Control of Excipients
4.1 Specifications 0 0 0 0 0 0
.j:o 4.2 Analytical Procedures 0 0 0 0 0 0
'0
4.3 Validation of Analytical Procedures 0 0 0 0 0 0
4.4 Justification of Specifications 0 0 0 0 0 0
4.5 Excipients of Human or Animal Origin 0 0 0 0 0 0
4.6 Novel Excipients 0 0 0 0 0 0
5. Control of Drug Product
5.1 Specification 0 0 0 0 0 0
5.2 Analytical Procedures 0 0 0 0 0 0
5.3 Validation of Analytical Procedures 0 0 0 0 0 0
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
5.4 Batch Analyses 0 0 0 0 0 0
5.5 Justification for Specification
6. Container Closure System 0 0 0 0 0 0
7. Stability 0 0 0 0 0 0
lJl 8. Other Information0
8.1 Executed Batch Records 0 0 0 0 0 0
8.2 Method Validation Package 0 0 0 0 0 0
8.3 Comparability Protocols 0 0 0 0 0 0
PRECLINICAL QUESTIONNAIRE
1) . Please estimate the percentage of preclinical sections of marketing
license applications which are of the following overall quality levels:
Excellent _%
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" .
2) How would you rate the applications reviewed within your agency,
according to the following criteria: .
Adherence to relevant guidelines
Excenent _%
Organization/presentation
Excellent _%
Please rate the" following topics of product license applications as to
the frequency of questions raised during the regulatory review
process, and the significance.of these questions to the product's
approval.
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NONCLINICAL
Frequency Significance
Rare Occasional Frequent. Minor Moderate Major
Pharmacology
1. Primary Pharmacodynamics 0 0 0 0 0 0
2. Secondary Pharmacodynamics 0 0 0 0 0 0
3. Safety Pharmacology 0 0 0 0 0 0
VI 4. Pharmacodynamic Drug Interactions 0 0 0 0 0 0w
Pharmacokinetics
1. Analytical Methods and Validation Reports 0 0 0 0 0 0
2. Kinetics (includiing in vivo studies of absorption and
excretion, including exretion in milk, of parent drug
and/or metabolites(s)) 0 0 0 0 0 0
3. Tissue Distribution 0 0 0 0 0 0
4. Metabolism 0 0 0 0 0 0
5. Pharmacokinetic Drug Interactions (nonclinical) 0 0 0 0 0 0
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
Toxicology
I. Single-Dose Toxicity 0 0 0 0 0 0
2. Repeat-Dose Toxicity 0 0 0 0 0 0
3. Genotoxicity
3.1 in vitro 0 0 0 0 0 0
Vl 3.2 in vivo 0 0 0 0 0 0
...
4. Carcinogenicity
4.1 Long-term studies ·0 0 0 0 0 0
4.2 Short-term studies (including range-finding studies) 0 0 0 0 0 0
5. Reproduction Toxicity
5.1 Fertility and early embryonic development 0 0 0 0 0 0
5.2 Embryo-fetal development 0 0 0 0 0 0
5.3 Prenatal and postnatal development, including maternal
function 0 0 0 0 0 0
6. Local Tolerance 0 0 0 0 0 0
Frequency Significance
Rare Occasional Frequent Minor Moderate Major
7. Other Toxicity Studies
7.1 Antigenicity 0 0 0 0 0 0
7.2 Immunotoxicity 0 0 0 0 0 0
7.3 Mechanistic studies 0 0 0 0 0 0
1Il 7.4 Dependence 0 0 0 0 0 01Il
5. Metabolites 0 0 0 0 0 0
6. Impurities 0 0 0 0 0 0
CLINICAL BIOPHARMACEUTICS QUESTIONNAIRE
1) Please estimate the percentage of clinical
pharmacokinetics/pharmacodynamics sections of marketing license
applications, which are of the following overall quality.levels:
Excellent _%
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·2) How would you rate the applications reviewed within your agency,
according to the following criteria:
Adherence to relevant guidelines
Excellent _%
. Organization/presentation
Excellent
Please rate the following topics of product license applications as to
the frequency of questions raised during the regulatory review process,
and the significance of these questions to the product's approval.
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CLINICAL BIOPHARMACEUTICS
Frequency Signitlcance
Rare Occasional Frequent Minor Moderate Major
Bioavailability and Biocquivalcncc
I. Bioavailability 0 0 0 0 0 0
2. Bioequivalence 0 0 0 0 0 0
3. In Vitro-In Vivo Comarisons 0 0 0 0 0 0
4. Bioanalytical and Analytical Methods for Human Studies 0 0 0 0 0 0
v,
00
Studies Using Human Biomaterials Pertinent to Absorption or Disposition
I. Plasma Protein Binding 0 0 0 0 0 0
2. Hepatic Metabolism and Interaction Studies 0 0 0 0 0 0
3. Studies Using Other Human Biomuterials [] 0 0 0 0 0
Human Pharmacokinetics (PK)
I. Healthy Subject PK and Initial Tokrubility Studies 0 0 0 0 0 0
2. Putient PK Hnd Initial Tolerability Studies [) 0 0 0 0 0
3. Intrinsic Factor PK Studies 0 0 0 0 0 0
4. Extrinsic Factor PK Studies 0 0 0 0 0 0
5. Population PK Studies 0 0 0 0 0 0
i,
Human Pharmacodynamics CPD)
Frequency
Rare Occasional Frequent
Significance
Minor Moderate Major
v,
'D
1. Healthy Subject PK and PKJPD Studies
2. Patient PK and PKJPD Studies
o
o
o
o
o
o
o
o
o
o
o
o
1\
CLINICAL QUESTIONNAIRE
1) Please estimate the percentage of clinical sections of marketing license
applications, which are of the following overall quality levels:
Excellent _%
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2) How would you rate the applications reviewed within your agency,
according to the following criteria:"
Adherence to relevant guidelines
Excellent _%
Organization/presentation
Excenent _%
61
3) How would you rate the adequacy of marketing applications to
demonstrate the efficacy of new products?
Excellent _%
How would you rate the adequacy of marketing applications to
demonstrate the safety of new products?
Excellent _%
Please rate the following topics of product license applications as to
the frequency of questions raised daring the regulatory review
process, and the significance of these questions to the product's
approv.al.
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3) How would you rate the adequacy ofmarketing applications to
demonstrate the efficacy of new products?
Excellent _%
How would you rate the adequacy of marketing applications to
demonstrate the safety of new products?
Excellent _%
Please rate the following topics of product license applications as to
the frequency of questions raised·doring the regulatory review
process, and the significance of these questions to the product's
approval.
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CLINICAL EFFICACY AND SAFETY
Frequency Significnnce
Rare Occasional Frequent Minor Moderate Major
Efficacy and Safety Studies
1. Controlled Clinical Studies Pertinent to the Claimed Indication 0 0 0 0 0 0
2. Uncontrolled Clinical Studies 0 0 0 0 0 0
0- 4. Analyses of Data From More Than One Study....,
(integrated summaries)
3.1 Efficacy 0 0 0 0 0 0
3.2 Safety 0 0 0 0 0 0
Drug Ahuse anti Overdose Information 0 0 0 0 0 0
Integrated Summary of Uenelits and 1{jsl,s 0 0 0 0 0 0
Appendix 2. Cirriculum Vitae f~r Fred Henry
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CURRICULUM VITAE
PERSONAL
Fred J. Hemy
461 Kingwood-Locktown Road, Flemington, NJ 08822
(908) 996-3740 ' ,
EDUCATION
Lehigh University, Management ofTechnology
Rutgers University, Biology/Chemistry -
EMPLOYMENT
ADVANCED BIOLOGICSllC, Lambertville, NJ
MS(anticipated June2002)'
BS(1983)/BA(1987)
EXECUTIVEDIRECTOR-REGULATORY 2001-Present
Provides consultation to clients on regulatory matters regarding US and international
submissions for clinical trial (IND, CTAlCTX) and registration (NDAJMAA) approval,
research plan design and associated Regulatory Agency interactions during the development
process. Manages compilation of regulatory submissions which Advanced Biologics prepares
on behalf of clients. Represents clients at US and ex-US Agency meetings regarding
development and registration issues. Responsible for overall management of regulatory
documentation collection for clinical studies conducted by Advanced Biologics.
BRISTOL-MYERS SQUIBB, Princeton, NJ
Director - FDA Liaison and Global RegulatoI)' Strategy 1999 to 2001
Responsible for FDA liaison and management of global regulatory team towards development
of new drug products and lifecycle management of in-line products within the
metabolic/endocrine therapeutic' area. This included providing guidance to project teams on
investigational product development programs, definition of registration strategies for new
drug products and coordination 'of meetings with regulatory authorities.
HOECHST MARION ROUSSEL, Bridgewater, NJ
Associate Director - Global Strategic Regulatorv Development 1998 to 1999
Responsible for providing input into strategic plans and achieving worldwide registration for
products within the antiinfective, metabolic/endocrine and oncology therapeutic areas.
Activities included coordination of regional regulatory activities in support of product
development and leadership of cross-functional submission teams responsible for compilation,
submission and approval of marketing applications.
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WYETH-AYERST~CH, Radnor, PA'
Associate Director - International Regulatory Affairs 1995 - 1998
Responsible. for coordinating efforts of marketing, R&D and subsidiary personnel· toward
development, compilation-and support of clinical trial and marketing authorization
applications submitted ex-US for various products in the CNS, female health and
cardiovascular therapeutic areas. .
Manager - International RegulatoI)' Affairs
Same responsibilities as Associate Director (see above).
MERCK AND COMPANY, INC., Rahway, NJ
1991-1995
Associate Manager - RegulatoI)' Liaison Worldwide March 1991 .;, August 1991
Responsible for regulatory activities necessary to achieve ex-US registration for products
within the metabolic/endocrine therapeutic area, including hypercholesterolemia and bone
metabolism products. Coordinated pharmaceutical, preclinical and clinical research personnel's
efforts toward development of marketing applications and the defense of such applications
once submitted.
Senior RegulatoI)' Associate <Registration)
Same responsibilities as Associate Manager(~ above).
1988-1991
Regulatorv Associate (Compliance) 1986 -1988
Responsible for QA of NDAIMAA documents and compliance of these submissions with
FDA and international regulations. Coordinated the compilation of chemistry/manufacturing,
preclinical and clinical reports into registration applications.
Information Analyst - Corporate Licensing 1985 - 1986
Responsible for maintenance of an internal database of compounds in development worldwide
and generation of reports for use in licensing projects. Maintained data file of all Merck
licensing transactions.
RUTGERS UNNERSITY, New Brunswick, NJ
Research Assistant. Chemistry Department
SOCIETY iVIEMBERSHIPS
Drug Information Association (DIA)
Regulatory Affairs Professional Society (RAPS) .
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1981-1984
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